The system provides comprehensive visibility within and outside the imaging plane. Credit: maxbelchenko / Shutterstock.

DeepSight Technology is set to unveil the ‘NeedleVue LiteCart Ultrasound System’ at the forthcoming Radiological Society of North America (RSNA) annual meeting.

At this event, the company expects to secure interest from clinicians willing to partner on clinical research for assessing the device.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

NeedleVue is a new ultrasound-guided needle technology that aims to improve precision and confidence during medical procedures. It is engineered to provide real-time visualisation of needles, guidewires, and catheters without the need for radiation or complex calibration.

It is set to simplify and democratise interventional procedures by embedding tiny sensors at the tip of various instruments. The device is set to simplify procedures, allowing clinicians to perform with increased confidence and precision.

This self-calibrating technology requires no advanced setup and is compatible with free-hand procedural workflows.

Its non-electrical and inert design is unaffected by temperature and magnetic fields, making it suitable for abdominal procedures such as biopsies, and potentially across various medical specialities.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The system operates effectively even with contrast agents, providing comprehensive visibility within and outside the imaging plane.

DeepSight’s NeedleVue marks a significant shift in needle guidance technology by providing real-time, precision needle tracking that is both portable and user-friendly, addressing the needs of healthcare providers for operational efficacy and optimised patient outcomes.

These features claim a paradigm shift in needle guidance technology, combining operational efficacy with optimised patient outcomes.

DeepSight Technology CEO and co-founder Nader Sadrzadeh said: “The potential applications for NeedleVue technology, including integrated solutions, are endless. NeedleVue aims to overcome existing limitations and represents the future of ultrasound-guided interventional procedures.”

The NeedleVue LiteCart Ultrasound system has not yet received authorisation from the US Food and Drug Administration and is currently unavailable for sale or use.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact